3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Postoperative Complications
1
Neoplasms
1
Hypothyroidism
1
Interventions
Oxaliplatin
5
Leucovorin
5
Fluorouracil
5
Gemcitabine
4
pirarubicin
2
liposomal doxorubicin
2
Surgical Procedures, Operative
2
Radiation
2
Paclitaxel
2
Neoadjuvant Therapy
2
Folfox protocol
2
Capecitabine
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
vocimagene amiretrorepvec
1
taxane
1
sulindac sulfone
1
remdesivir
1
pembrolizumab
1
nimotuzumab
1
methylnaltrexone
1
lenvatinib
1
irinotecan sucrosofate
1
carbon-11 acetate
1
bavituximab
1
alovudine
1
aflibercept
1
Thyroxine
1
Therapeutics
1
Temozolomide
1
Taxes
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Withdrawn
×
Thyroxine
×
Clear all
NCT02548715
2022-07-13
LSHT
University of Alberta
Phase 2/3
Withdrawn